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Background: Although superiority of second generation drug eluting stent (DES)
than ﬁrst generation DES is suggested, that efﬁcacy has not been demonstrated by
recent randomized trials. Syntax score-based assessment for outcomes of PCI may
help to identify priority of second generation DES.
Methods: We investigated 1264 of all comer patients who underwent percutaneous
coronary intervention (PCI) with unrestricted use of DES either ﬁrst generation
(Cypher;531 and Taxus;378) or second generation (Xience or Promus;190 and
Nobori;165), and compared between them. We employed syntax score for evalu-
ating severity of coronary artery disease, and patients were classiﬁed into three
groups by tertile of its score (low; 1-11, intermediate; 12-24, and high; >25).
Primary endpoint of this analysis was major adverse cardiac event (MACE)
comprised from all cause death, non-fatal myocardial infarction, and any target
lesion revascularization.
Results: Of all, based on survival analysis, occurrence of MACE was lower in patients
with second generation DES than ﬁrst generation DES (median: 715days, ﬁrst; 16.3%
vs. second; 11.8 %, P¼0.03). According to syntax score-based analysis (low;7.23,
intermediate;17.74, high;37.611) for occurrence of MACE, superiority of second
generation DES was seen among patients with high syntax score (ﬁrst; 24.1% vs.
second; 15.6%, logrank: P¼0.05) in contrast to similar results of low (9.8% vs.6.8%,
P¼0.62) and intermediate (16.2% vs. 15.3%, P¼0.86) syntax score. According to
multivariate analysis, statin therapy (hazard ratio:HR;0.56, 95% conﬁdence
interval:95%CI; 0.39-0.79, P¼0.001), CKD(eGFR<60ml/min, HR;1.79,95%CI;1.28-
2.50,P¼0.001), and syntax score (HR;1.02, 95%CI; 1.01-1.03, P<0.0001) was
independent predictor of occurrence of MACE.
Conclusions: In this all comer study, superiority of second generation DES than
ﬁrst generation DES was seen in patients with high syntax score. Newer technology
of DES may contribute to improve the outcomes of such high risk patients.
Assessment of lesion complexity was important to evaluate outcomes of PCI using
DES. And we should pay attention to statin therapy and CKD to improve outcomes
of all patients.
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Background: the reduction of arterial wall inﬂammation and delayed healing could
play an important role in decreasing adverse events in complex patients such as
diabetics. Biodegradable polymers (bp) may have an advantage over non-erodable
polymers because any tendency to inﬂammation is eliminated after the polymer
degrades. Aim of the present study was to assess the efﬁcacy of bp-Biolimus-Eluting
Stent (bp-BES) in a large series of consecutive diabetic patients.
Methods: from 2008 to 2012, consecutive diabetic patients who underwent PCI with
bp-BES implantation for de novo coronary artery lesions in six European tertiary care
centres were retrospectively selected and analyzed. Primary endpoints were the
incidence of target lesion revascularization (TLR) and target vessel failure (TVF,
deﬁned as cardiac death, MI and target vessel revascularization – TVR-) at long term
follow-up.
Results: a total of 650 patients were included in the analysis. Mean age was 66.49.7
years and 73.4% of patients were males. IDDM was present in 32.8% of patients and
92.9% had at least one additional cardiovascular risk factor. Clinical presentation was
stable angina in 48.5% of cases, followed by ACS/NSTEMI (36.6%), STEMI (8.6%)
and silent ischemia (6.3%). Multivessel disease was present in 46.1% of patients and
number of vessel and lesion treated per patient were 1.370.53 and 1.580.64
respectively. Total stent length per patient was 38.418.6mm and stent per patient
ratio was 1.810.71. Median follow-up was 391 days (IQR 290-661). During the
hospital stay, no patient died and the incidence of TVF was 0.7%. At follow-up,
cumulative incidence of cardiac death was 1.3%, MI rate was 1.1%, TLR and TVR
rates were 7.9% and 11.9% respectively. Deﬁnite/probable ST occurred in 1.4% of
patients . Time to event analysis showed a TLR and TVF-free survival at median FU
and at 661 days of 94.7/91% and 91.2/86.1% respectively. At multivariate Cox
regression, IDDM was found to be independent predictor of TVF (HR:2.18; 95%CI:
1.32–4.89; p 0.02) at long-term FU.
Conclusions: use of bp-BES in a large unselected population of diabetic patients was
related with excellent results both in terms of TLR and TVF at short and long term FU.B62 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-191
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Background: Diabetes mellitus (DM) is an independent predictor of adverse clinical
events after drug-eluting stent implantation. New generation drug-eluting stents (DES)
have demonstrated their mid-term effectiveness and safety in patients with DM.
However, limited data exists for long-term safety and efﬁcacy. Therefore, we inves-
tigated the long-term clinical outcomes of new generation DES implantations in
patients with DM and single vessel disease.
Methods: We prospectively enrolled 600 consecutive patients. Of these, 418 patients
were non-diabetic, whereas 182 had DM. All patients received zotarolimus- or
everolimus-eluting stent. The major adverse cardiac events (MACE) including death,
non-fatal myocardial infarction (MI) and target lesion revascularization (TLR) were
deﬁned as primary end points. Stent thrombosis was also evaluated according to the
Academic Research Consortium Deﬁnition.
Results: The overall MACE rates were higher in patients with DM, and the difference
was statistical signiﬁcance (5.26% in non-DM patients vs 10.98% in DM patients,
p¼0.01) during the 3 years follow-up period. Also the overall death (cardiac/non-
cardiac) was statistically signiﬁcantly higher in DM patients as compared with non-
DM patients (3.29% vs 0.47%, p¼0.01 respectively). Rates of TLR (4.06% non-DM
vs 4.94% DM patients, p¼0.66) and non-fatal MI (0.71% non-DM vs 2.74% DM
patients, p¼0.05) were not signiﬁcantly different between the 2 groups. Notably,
patients with DM had a statistically signiﬁcantly increased deﬁnite stent thrombosis
rate (0.79% non-DM vs 3.29% DM, p¼0.02).
Conclusions: Our study demonstrated that the long term safety of the new generation
DES is still a concern in patients with DM, as the overall death and the deﬁnite stent
thrombosis rate were increased.
TCT-192
One Year Clinical And Angiographic Outcomes After Everolimus- And
Paclitaxel-eluting Stent Implantation For Small Coronary Vessels In Diabetic
Patients: Sub-analysis From PLUM And SACRA Registries
Yuji Oikawa1, Tadanori Aizawa1, Ryo Gotoh2, Ren Kawaguchi3, Yuya Nakagawa4,
Kenya Nasu5, Atsunori Okamura6, Shinichi Shirai7, Takahide Suzuki8,
Takahiko Suzuki9, Yoshihiro Takeda10, Masaki Tanabe11, Yuichi Ujiie12
1The Cardiovascular Institute, Tokyo, Japan, 2Shuwa General Hospital, Kasukabe,
Saitama, 3Gunma Prefectural Cardiovascular Center, Maebashi, Gunma, 4Tokeidai
Memorial Hospital, Sapporo, Hokkaido, 5Toyohashi Heart Center, Toyohashi, Aichi,
6Sakurabashi-Watanabe Hospital, Osaka, Japan, 7Kokura Memorial Hospital,
Kitakyushu, Fukuoka, 8JA Hokkaido Engaru Kosei General Hospital, Monbetsugun,
Japan, 9Toyohashi Heart Center, Toyohashi, Japan, 10Rinku General Medical Center,
Izumi-Sano, Japan, 11Dai-ni Okamoto General Hospital, Kyoto, Japan, 12Hoshi
General Hospital, Fukushima, Japan
Background: There are limited clinical follow-up data after single drug-eluting stent
implantation for small coronary artery diseases in diabetic patients. The aim of this
study is to evaluate the one-year clinical and angiographic outcomes following small
coronary stenting between everolimus- (EES) and paclitaxel-eluting stent (PES) in
diabetic patients.
Methods: PLUM (PROMUS/Xience V Everolimus-ELUting Coronary Stent for
sMall coronary artery disease: 264 patients with 279 lesions) and SACRA (SmAll
CoronaRy Artery treated by TAXUS Liberté: 245 patients with 258 lesions) registries
are prospective, multicenter registries to assess the efﬁcacy of single EES and PES in
patients with small coronary artery diseases. Inclusion criteria were 1) Lesions >75%
diameter stenosis in vessels <2.5mm in diameter, 2) lesion length <28mm. From
these registries, 247 lesions in 235 diabetic patients were selected to evaluate one year
clinical and angiographic results.
Results:Major adverse cardiac events between the two groups were similar, however,
late loss, one year target lesion revascularization and binary restenosis rates were
signiﬁcantly lower in EES group (Table).j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
